Injectable Drug Delivery: Market Impact and Industry Trends

Publication Date	October 2006
Publisher	Arrowhead
Product Type	Report
Pages	130
ISBN Number	not applicable
Product Code	ARR00011

Price

£1,180.00
approximately: $1,752 | €1,389

PDF immediate delivery

Order above formats by FAX

Summary

As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances.

The global market for drug delivery technology is worth in excess of US$25 billion in sales. Given its predicted annual growth of 15 percent, the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists. According to Arrowhead Publishers' new report entitled Injectable Drug Delivery: Market Impact and Industry Trends, injectables currently account for an estimated 15 percent of the global drug delivery market, with the US being the leading individual market.

Key features of this report:

Overview of the drug delivery environment
In-depth analysis of the injectable drug delivery industry, including main types and main marketed systems, and their advantages and disadvantages
Comprehensive facts and figures for the injectable drug delivery market, including main players and key therapeutic areas
Future trends in the injectables marketplace, shaped by medical and technological advances as much as demographic and epidemiological changes and industry needs
Outlook for the injectable drug delivery technology

Who should buy this report?

Stakeholders in the injectable drug delivery market
Companies interested in understanding the impact and implications of securing the correct injectable drug delivery technology in terms of product placement, lifecycle management and competition in the marketplace
Companies interested in understanding future opportunities in the injectable drug delivery sector provided by a combination of factors, including changing public health needs
Pharma/biotech companies wishing to identify potential injectable drug delivery areas for partnerships and collaboration in order to examine a variety of profit maximization strategies

Content

1. Executive Summary
2. Introduction to Drug Delivery
- 2.1 Drug Delivery Technologies and Pharmaceutical Revenues
- 2.2 Drug Delivery Technologies and Wider Healthcare Market
3. Overview of Injectable Drug Delivery
- 3.1 Advantages and Disadvantages of Injectable Delivery
- 3.2 Types of Injectable Drug Delivery
4. Main Categories of Marketed Injectable Drug Delivery Systems
- 4.1 Sustained Release Injectable Systems
- 4.2 Advantages of Injectable Sustained-Release Formulations
- 4.3 Liposomal Systems
- 4.4 Advantages of Injectable Liposomal Formulations
- 4.5 Needleless Systems
- 4.6 Advantages of Injectable Needleless Formulations
5. Injectable Drug Delivery Market - Facts and 5.1 Injectable Drug Delivery Market Overview
- 5.2 Key Therapeutic Areas for Injectable Drug Delivery
- 5.3 Acromegaly
- 5.4 Age-Related Macular Degeneration
- 5.5 Crohn's Disease
- 5.6 Diabetes
- 5.7 Hepatitis C
- 5.8 Multiple Sclerosis
- 5.9 Neutropenia
- 5.10 Oncology
- 5.11 Pain
- 5.12 Psoriasis
- 5.13 Rheumatoid Arthritis
6. Drug Classes Appropriate for Injectable Drug Delivery
7. Main Players and Partnerships in the Injectable Drug Delivery Market
8. Key Company Involvement in the Field of Injectable Drug Delivery
- 8.1 Alkermes
- 8.2 ALZA
- 8.3 Aradigm
- 8.4 Bioject
- 8.5 Enzon
- 8.6 Ethypharm
- 8.7 MacroMed
- 8.8 Nektar Therapeutics
- 8.9 QLT
- 8.10 SkyePharma
9. Sales of Products Utilizing Injectable Drug Delivery Technology
10. Profiles of Key Products Using Injectable Drug Delivery Technology
- 10.1 Neulasta (Nektar/Amgen)
- 10.2 PEGASYS (Roche/Nektar)
- 10.3 PEG-Intron (Schering-Plough)
- 10.4 Risperdal Consta
- 10.5 Sandostatin (Novartis)
- 10.6 Vivitrol (Alkermes)
11. Recent Launches and Approvals in the Field of Injectable Drug Delivery
- 11.1 August 2006
- 11.2 July 2006
- 11.3 May 2006
- 11.4 April 2006
- 11.5 February 2006
- 11.6 January 2006
12. Current Research and Profiles of Key Pipeline Products in the Field of Injectable Drug Delivery
- 12.1 Cimzia (Nektar)
- 12.2 Mircera/CERA (Nektar)
- 12.3 Paliperidone Palmitate (Johnson & Johnson)
- 12.4 Intraject Sumatriptan (Zogenix)
13. Future of Injectable Drug Delivery Technology
- 13.1 Emerging Injectable Drug Delivery Technologies
- 13.2 Emerging Therapeutic Targets for Injectable Drug Delivery
- 13.3 Future Therapeutic Targets for Injectable Drug Delivery
- 13.4 New Technology and the Injectable Drug Delivery Market
- 13.5 New Threats to the Injectable Drug Delivery Market
- 13.6 New Healthcare Needs and the Injectable Drug Delivery
14. Outlook for Injectable Drug Delivery Technology
List of Diagrams
- Diagram 4.1 Rheumatoid Arthritis Treatment Guidelines
- Diagram 4.2 The American College of Rheumatology Criteria (ACR) Criteria
List of Tables
- Table 2.1 Drivers of New Drug Delivery Technologies
- Table 2.2 Advantages of New Drug Delivery Technology
- Table 3.1 Types of Injectable Delivery
- Table 4.1 Key Companies in the Needleless Drug Technology Market
- Table 5.1 Leading MS Therapy Delivery Routes and Dosage
- Table 5.2 Key Biologics for the Treatment of Psoriasis
- Table 5.3 Administration Methods of Main RA Therapies
- Table 7.1 Leading Injectable Drug Delivery Companies 2005, Key Products and Sales 2005 ($ mn)
- Table 7.2 Novartis' Pipeline Major Drug Delivery Partners
- Table 8.1 Key Details of Main Companies in the Field of Injectable Drug Delivery
- Table 8.2 Alkermes' Injectable Drug Delivery Portfolio, 2006
- Table 8.3 Bioject's Injectable Drug Delivery Portfolio, 2006
- Table 8.4 Enzon's Injectable Drug Delivery Portfolio, 2006
- Table 8.5 Ethypharm's Injectable Drug Delivery Portfolio, 2006
- Table 8.6 MacroMed's Injectable Drug Delivery Portfolio, 2006
- Table 8.7 Nektar's Injectable Drug Delivery Portfolio, 2006
- Table 8.8 SkyePharma's Injectable Drug Delivery Portfolio, 2006
- Table 9.1 Key Injectable Drug Delivery Products, 2004-2005 ($ mn)
- Table 10.1 GH Suppression During Long-Term Treatment with Immediate Release Sandostatin Injection and Sandostatin LAR Depot
- Table 10.2 Comparison of Acromegaly Symptoms with Immediate Release Sandostatin Injection and Sandostatin LAR Depot as Reported by Patients
- Table 13.1 Key Injectable Drug Delivery R&D Pipeline Drugs, 2006
- Table 13.2 Other Viral and Bacterial Infections to Which Injectable Technology is Applicable
- Table 13.3 Emerging Therapeutic Areas for Injectable Drug Delivery
- Table 13.4 DOR BioPharma Drug Delivery Portfolio, 2006
- Table 14.1 Drivers and Restraints of Injectable Drug Delivery
List of Figures
- Figure 4.1 Patient Perception of Iject and Associated Pain
- Figure 8.1 Illustration of ALZAMER's PLGA Solvent Control over Protein Release
- Figure 8.2 Advanced PEGylated Drug Molecules
- Figure 8.3 Four Stages of Photodynamic Therapy
- Figure 12.1 Illustration of NanoCrystal Dispersion's Advantages
- Figure 13.1 Comparison of Morphine Delivery Technologies: Oral, Injectable and Transmucosal
List of Graphs
- Graph 5.1 2005 Sales of Leading MS Therapies
- Graph 5.2 2005 Sales of Leading Psoriasis Biologics
- Graph 5.3 2005 Sales of Leading RA Therapies
- Graph 7.1 Leading Injectable Drug Delivery Companies, Combined Key Product Values 2005 ($ mn)
- Graph 7.2 Leading Companies Active in Injectable Drug Delivery Development, Number of Products
- Graph 9.1 Top Ten Products Utilizing Injectable Delivery, Global Sales 2005 ($ mn)